Acute myeloblastic leukemia (AML)was diagnosed in a 54-year-old male, a chronic hepatitis B surface antigen (HBsAg) carrier, in June, 1983. Prompt remission was achieved, and maintenance and intensification chemotherapy were given for five years. He was readmitted in March, 1988 because of a mass in the liver and was diagnosed as having hepatocellular carcinoma (HCC). Curative right segmentectomy was performed in May, 1988. In December, 1988, transitional cell carcinoma of the bladder was discovered, and resected transurethrally. These secondary neoplasms, HCCand bladder cancer, were thought to be associated with the long-term chemotherapy given for the AML.
hematological malignancy have increased with recent advances in diagnostic techniques and cancer chemotherapy (1). Wereport here a case of hepatocellular carcinoma (HCC) and bladder cancer occurring as complications following five years of chemotherapy for acute myeloblastic leukemia (AML) .
CASE REPORT
A 54-year-old man was first admitted to our hospital in June, 1983 because of fever and petechiae. He had smoked 20 cigarettes daily between 1965 and 1980 but as having HCCand curative right segmentectomy was performed in May, 1988 after transcatheter arterial embolization. The gross specimen weighed 2,100 g and contained a single, well circumscribed HCC measuring 17.1 x 12.7 cm (Fig. 3) ofEdmonson II type associated with chronic hepatitis. After surgical resection of the hepatic tumor, the AFP level decreased to 10.7 ng/ml and HBsAgand hepatitis B virus associated-DNA polymerase (HBV-DNA-P) became undetectable in the serum within one month.
In December, 1988, the patient suffered macrohematuria and was admitted to the Departmentof Urology. Transurethral resection of a grade II papillary transitional cell carcinoma of the bladder (Fig. 4) was performed in December, HBsAgand HBV-DNA-P have been negative for 1 year and the patient has been doing well since January, 1989. The HBsAgclearance observed after resection in our patient confirmed that HBsAgwas present exclusively in the tumor cells. Thus it was suggested that HBVcould have been one factor contributing to the development of HCCin the present case. drugs that the patient received, EDXis the only one that has been shown to be a humancarcinogen (8, 9). There is abundant literature about bladder cancer following administration of this agent (10-16). Therefore we speculate that the bladder mucosa was damaged and humoral and cell-mediated immune defense was suppressed by EDX,and that the other combined drugs promoted the transformation to cancer. Although patients with bladder cancer following EDXtherapy have been reported to experience hemorrhagic cystitis during therapy (1 1 , 14) , this did not occur in our patient. Bjergaard et al reported that no increased risk of bladder carcinoma was seen in a large cohort study of 471 patients in whomhemorrhagic cystitis developed (1 6). Tobaccosmoking and exposure to compounds such as aromatic amines are knownto induce carcinoma of the urinary bladder (17, 18 
